SANTIAGO, Chile (AP) — In a recent incident, a hantavirus outbreak on the cruise ship MV Hondius raised serious health concerns as passengers began falling ill from this rare rodent-borne virus. By May 2026, there were no available treatments or vaccines for those affected or to prevent further infections, highlighting the significant gaps in public health responses to such viruses.
The hantavirus, part of a family of viruses known for decades and present globally, is especially notable in this case due to the Andes virus, which has the potential to spread between humans. This particular outbreak underscored the public health risks associated with hantaviruses that, while rare, can have extremely deadly consequences. Teams from multiple countries, including Chile, Argentina, and the United States, have engaged in extensive research efforts to develop drugs and vaccines, but funding has been limited due to the infrequency of outbreaks.
Recent developments reported on May 10, 2026, suggest there may be hope. Researchers published findings indicating that tocilizumab, a drug typically used to treat autoimmune diseases, could help hantavirus patients combat severe symptoms. In an Argentinian hospital, this drug was administered to several patients battling hantavirus pulmonary syndrome, resulting in a survival rate of 80% for those treated, compared to the standard care group, pointing to a need for further investigation into this treatment.
The Andes virus, responsible for the recent cruise ship incident, has evolved into a focal point for research because of its capability to transmit from person to person. Virologist María Inés Barría highlighted the risks associated with this unique strain, noting that, tragically, three out of 13 suspected cases among the cruise ship passengers resulted in death.
In Chile, as of May 2026, the Ministry of Health reported 15 hantavirus-related deaths and 42 confirmed cases, while Argentina faced 32 deaths and 102 cases since June 2025. In the United States, historical data indicates that approximately 35% of hantavirus cases have ended in death since tracking began in 1993.
Efforts to combat hantavirus include research led by Barría and international collaborators, who are investigating the use of cloned antibodies from survivors to develop effective treatments. Previous studies in animals have shown promise, yet funding for human trials has been challenging, particularly as pandemic resources were redirected.
Additionally, efforts are underway to develop vaccines specifically targeting various strains of hantavirus. Although some vaccines for Old World hantaviruses exist, the World Health Organization confirms no licensed vaccines for current strains are available. Encouragingly, early trials are underway for a vaccine aimed at the Andes virus that has shown potential in generating immune responses in participants.
Despite these efforts, significant obstacles remain in developing effective treatments and vaccines for hantavirus. Dr. Paul Bollyky from Stanford Medical Center emphasized the difficulties in garnering and maintaining support for rare diseases, noting the challenges posed by sporadic outbreaks which complicate clinical trials. The unpredictability of these infections in terms of exposure makes advancing research frustrating for many in the medical community.
The recent outbreak on the MV Hondius serves as a reminder of the urgent need for sustained investment and research in rare viral diseases like hantavirus. Increased attention may lead to improved collaboration among healthcare workers, researchers, and funding bodies to ensure that vital treatments and vaccines are developed to protect against future outbreaks.
